Literature DB >> 11383974

Pharmacotherapy of mental illness--a historical analysis.

T A Ban1.   

Abstract

The history of pharmacotherapy of mental illness can be divided into three periods. Introduction of morphine, potassium bromide, chloral hydrate, hyoscine, paraldehyde, etc., during the second half of the 19th century (first period), led to the replacement of physical restraint by pharmacological means in behavior control. Introduction of nicotinic acid, penicillin, thiamine, etc., during the first half of the 20th century (second period), led to significant changes in the diagnostic distribution of psychiatric patients; psychoses due to cerebral pellagra, and dementia due to syphilitic general paralysis virtually disappeared from psychiatric hospitals, and the prevalence of dysmnesias markedly decreased. Treatment with therapeutically effective drugs of mania, schizophrenia, depression, bipolar disorder, generalized anxiety disorder, panic disorder, obsessive compulsive disorder, Alzheimer's disease, etc., during the second half of the 20th century (third period), brought to attention the heterogeneity of the populations within the diagnostic categories of schizophrenia and depression. Introduction of the first set of psychotropics and the spectrophotofluorimeter during the 1950s triggered the development of neuropsychopharmacology. Introduction of genetic technology for the separation of receptor subtypes in the 1980s opened the path for the "tailoring" of psychotropic drugs by the dawn of the 21st century, to receptor affinities.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11383974     DOI: 10.1016/s0278-5846(01)00160-9

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  11 in total

Review 1.  Gene expression profiling with DNA microarrays: advancing our understanding of psychiatric disorders.

Authors:  Julie Pongrac; Frank A Middleton; David A Lewis; Pat Levitt; Károly Mirnics
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

2.  A brief historicity of the Diagnostic and Statistical Manual of Mental Disorders: issues and implications for the future of psychiatric canon and practice.

Authors:  Shadia Kawa; James Giordano
Journal:  Philos Ethics Humanit Med       Date:  2012-01-13       Impact factor: 2.464

3.  Who pioneered the use of antipsychotics in North America?

Authors:  Emmanuel Stip
Journal:  Can J Psychiatry       Date:  2015-03       Impact factor: 4.356

Review 4.  The role of cytochromes P450 in the metabolism of selected antidepressants and anxiolytics under psychological stress.

Authors:  Nina Zemanova; Pavel Anzenbacher; Eva Anzenbacherova
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2022-04-12       Impact factor: 1.245

5.  Pharmacological and combined interventions for the acute depressive episode: focus on efficacy and tolerability.

Authors:  Andre R Brunoni; Renerio Fraguas; Felipe Fregni
Journal:  Ther Clin Risk Manag       Date:  2009-11-18       Impact factor: 2.423

6.  Efficacy and tolerability of aripiprazole in patients with schizophrenia & schizoaffective disorders.

Authors:  R K Chavda; L Laxmi; B S Nair; K Gandewar
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

7.  Grand Challenge in Psychopharmacology: Setting Priorities to Shape a Bright Future.

Authors:  Roberto Ciccocioppo
Journal:  Front Psychiatry       Date:  2017-02-10       Impact factor: 4.157

8.  Fifty years chlorpromazine: a historical perspective.

Authors:  Thomas A Ban
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

9.  The history of barbiturates a century after their clinical introduction.

Authors:  Francisco López-Muñoz; Ronaldo Ucha-Udabe; Cecilio Alamo
Journal:  Neuropsychiatr Dis Treat       Date:  2005-12       Impact factor: 2.570

10.  The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs.

Authors:  Robin L Carhart-Harris; Robert Leech; Peter J Hellyer; Murray Shanahan; Amanda Feilding; Enzo Tagliazucchi; Dante R Chialvo; David Nutt
Journal:  Front Hum Neurosci       Date:  2014-02-03       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.